New screening hub to identify COVID-19 drugs funded in Scotland
LifeArc and the Medical Research Council have funded a new drug screening facility that will be established to accelerate COVID-19 drug discovery.
List view / Grid view
LifeArc and the Medical Research Council have funded a new drug screening facility that will be established to accelerate COVID-19 drug discovery.
Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.
Researchers suggest that identifying new treatments for autoimmune diseases requires studying the immune system AND target tissues together.
Computational drug screening has shown that chemotherapy drug pralatrexate could potentially be repurposed to treat COVID-19.
The study found five key genetic differences when they compared sequences from severe COVID-19 patients to healthy individuals.
Two drugs, Nefiracetam and PHA 543613, were able to return neuronal signalling to near normal in organoids derived from patients with the autism spectrum disorder, Rett syndrome.
Investigators found that red propolis can kill schistosomes at all stages of development and therefore suggest it could be highly effective for treating schistosomiasis.
The new study shows how SARS-CoV-2 significantly remodels cellular processes in just an hour and identifies potential drug targets and therapeutics for COVID-19.
A new study shows that methacycline, a commonly used antibiotic, can reduce the neurological damage caused by Zika virus infections in mice.
The candidates were screened based on their similarity to hydroxychloroquine and tested for efficacy against SARS-CoV-2 in vitro.
Researchers have identified hepatitis C drugs that can inhibit the SARS-CoV-2 main protease, which enables the coronavirus to reproduce.
Anti-inflammatory therapies for inflammatory bowel disease could aid recovery from COVID-19 as they target an enzyme involved in both diseases.
Enosi Life Science researchers Sir Marc Feldmann, Dr H Michael Shepard and Dr Fiona McCann explain why anti-TNF therapies may be effective in treating COVID-19 associated cytokine storms and other inflammatory conditions.
A team showed that high doses of favipiravir can treat hamsters infected with SARS-CoV-2, whereas hydroxychloroquine has no effect.
Breaking down or slowing the production of a hyaluronan jelly which builds up in the lungs of some severe COVID-19 patients could reduce respiratory distress and prevent death.